BioNexus Gene Lab Corp Common stock (BGLC) — Cash Flow Reinvestment Rate
BioNexus Gene Lab Corp Common stock (BGLC) has a Cash Flow Reinvestment Rate of 0.14x as of December 2022, reinvesting $66.93K (capex $17.03K plus investments $-49.90K) from operating cash flow of $474.47K. See BioNexus Gene Lab Corp Common stock free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
BioNexus Gene Lab Corp Common stock Cash Flow Reinvestment Rate (2017–2022)
Historical reinvestment intensity for BioNexus Gene Lab Corp Common stock across 4 annual periods. For the full cash flow conversion analysis, see BGLC cash generation efficiency.
Annual Cash Flow Reinvestment Rate for BioNexus Gene Lab Corp Common stock (2017–2022)
Year-by-year capital reinvestment analysis for BioNexus Gene Lab Corp Common stock. See BGLC financial flexibility index to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 0.93x | $504.67K | $544.03K | $54.17K | ▼ -98.3% |
| 2021 | 55.96x | $512.61K | $9.16K | $3.16K | ▲ +6082.7% |
| 2020 | 0.91x | $500.19K | $552.68K | $421.62K | ▼ -1.1% |
| 2017 | 0.92x | $326.90K | $357.22K | $314.82K | — |